Drug safety evaluation of desogestrel

Expert Opinion on Drug Safety

Volumn 12, Issue 3, 2013, Pages 433-444

  Scala, Carolina ^a   Leone Roberti Maggiore, Umberto ^a   Remorgida, Valentino ^a   Venturini, Pier Luigi ^a   Ferrero, Simone ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Adverse events; Contraception; Desogestrel; Etonorgestrel; Hormone replacement therapy; Implanon ; Nexplanon ; Progestins; Side effects; Tolerability

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ESTRADIOL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; ETHINYLESTRADIOL; ETONOGESTREL; LEVONORGESTREL; PLACEBO;

ACNE; AMENORRHEA; BLOOD PRESSURE; BODY WEIGHT; BREAST TENSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTRACEPTIVE DEVICE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; DYSMENORRHEA; EDEMA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN DEFICIENCY; HEMATOMA; HIRSUTISM; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERTENSION; HYPERTRICHOSIS; LIBIDO DISORDER; LIPID METABOLISM; MALAISE; MASTALGIA; MAXIMUM PLASMA CONCENTRATION; MEDICAL DEVICE COMPLICATION; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENTAL DISEASE; MENTAL INSTABILITY; META ANALYSIS (TOPIC); METRORRHAGIA; MOOD CHANGE; MORBIDITY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; ORAL CONTRACEPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN DISEASE; SPOTTING; URINARY TRACT INFECTION; VAGINA BLEEDING; VAGINITIS; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; WITHDRAWAL BLEEDING;

BREAST NEOPLASMS; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; DRUG THERAPY, COMBINATION; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS;

EID: 84876585363     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.788147     Document Type: Review

References (82)

1. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010;82:410-17
2. McClamrock HD, Adashi EY. Pharmacokinetics of desogestrel. Am J Obstet Gynecol 1993;168:1021-8 (Pubitemid 23094297)
3. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-78 (Pubitemid 43231449)
4. Schindler AE, Compagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2008;61:171-80
5. Korhonen T, Tolonen A, Uusitalo J, et al. The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol 2005;60:69-75 (Pubitemid 40942783)
6. Gentile DM, Verhoeven CHJ, Shimada T, Back DJ. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther 1998;287:975-82 (Pubitemid 29131610)
7. Verhoeven CHJ, Krebbers SFM, Wagenaars GN, Vos RME. In vitro and in vivo metabolism of desogestrel in several species. Drug Metab Dispos 1998;26:927-36 (Pubitemid 28452061)
8. Timmer CJ, Apter D, Voortman G. Pharmacokinetics of 3-keto-desogestrel and ethinyl estradiol released from different types of contraceptive vaginal rings. Contraception 1990;42:692-42
9. Back DJ, Grimmer SFM, Shenoy N, Orme MLE. Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. Contraception 1987;35:619-27
10. Jung-Hoffmann C, Fitzner M, Kuhl H. Oral contraceptives containing 20 or 30 μg ethinyl estradiol and 150 μg desogestrel: pharmacokinetics and pharmacodynamic parameters. Horm Res 1991;36:238-46
11. Wenzl R, van Beek A, Schnabel P, Huber J. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception 1998;58:283-8 (Pubitemid 29036549)
12. Verhoeven CH, Gloudemans RH, Peeters PA, et al. Excretion and metabolism of desogestrel in healthy postmenopausal women. J Steroid Biochem Mol Biol 2001;78:471-80 (Pubitemid 34014828)
13. Hammond GL, Langley MS, Robinson PA, et al. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. Fertil Steril 1984;42:44-51 (Pubitemid 14086149)
14. Hall KS, Trussell J, Schwarz EB. Progestin-only contraceptive pill use among women in the United States. Contraception 2012;86:653-8
15. Grove D, Hooper DJ. Doctor contraceptive-prescribing behaviour and women's attitudes towards contraception: two European surveys. J Eval Clin Pract 2011;17:493-502
16. Kivela A, Ruuskanen M, Agren U, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonrgestrel (30 μg/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J contracept Reprod Health Care 2001;6:71-7 (Pubitemid 32735337)
17. Ahrendt HJ, Karck U, Pichl T, et al. Effects of an oestrogen-free DSG containing oral contraceptive in women with cyclical symptoms: results from two studies on oestrogen-related symptoms and dysmenorrhea. Eur J contracept Reprod Health Care 2007;12:354-61 (Pubitemid 350146719)
18. Rice C, Killick S, Hickling D, Coeling Bennink H. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod 1996;11:737-40 (Pubitemid 26142168)
19. Collaborative Study Group on the Desogestrel-containing Progestogen-only pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day. Eur J Contracept Reprod Health Care 1998;3:169-78
20. Bengiano G, Primiero FM. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann N Y Acad Sci 2003;997:163-73 (Pubitemid 38491072)
21. World Health Organization (WHO). Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. 2nd edition. WHO, Geneva; 2000
22. Belsey EM, Machin D, d'Arcangues C; World Health Organization Special Program of Research, Development and Research Training in Human Reproduction. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception 1986;34:253-60 (Pubitemid 17177017)
23. Summary of product characteristics for Implanon. Organon 2002;1-4
24. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonorgestrel (30 μg/day) on lipid metabolism. Contraception 2001;64:295-9 (Pubitemid 34075556)
25. Winkler UH, Howie H, Bühler K, et al. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrel. Contraception 1998;57:385-92 (Pubitemid 28348071)
26. Thompson AK, Przemska A, Vasilopoulou D, et al. Combined oral contraceptive pills containing desogestrel or drospirenone enhance large vessel and microvasculature vasodilatation in healthy premenopausal women. Microcirculation 2011;18:339-46
27. Benagiano G, Primiero FM, Farris M. Clinical profile of contraceptive progestins. Eur J Contracept Reprod Health Care 2004;9:182-93 (Pubitemid 39539580)
28. Anttila L, Kunz M, Marr J. Bleeding pattern with drospirenone 3 mg+ ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception 2009;80:445-51
29. Gruber DM, Huber JC, Melis GB, et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinyl estradiol 20 μg and drospirenone 3 mg with a 21-day regimen of ethinyl estradiol 20 μg and desogestrel 150 μg. Treat Endocrinol 2006;5:115-21
30. Endrikat J, Cronin M, Gerlinger C, et al. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 μg ethinyl estrediol and 75 μg gestodene and a 21-day regimen with 20 μg ethinyl estrediol and 150 μg desogestrel. Contraception 2001;64:201-7 (Pubitemid 33042591)
31. Akerlund M, Røde A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol. Br J Obstet Gynaecol 1993;100:832-8 (Pubitemid 23280566)
32. Bruni V, Croxatto H, De La Cruz J, et al. A comparison of cycle control and effect on well-being of monophasic gestodene, triphasic gestodene and monophasic desogestrel-containing oral contraceptives. Gynecol Endocrinol 2000;14:90-8 (Pubitemid 30307216)
33. Kirkman RJE, Pedersen JH, Fioretti P, Roberts HE. Clinical comparison of two low-dose oral contraceptives, Minulet-and Mercilon-, in women over 30 years of age. Contraception 1994;33:46
34. WHO. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8
35. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93 (Pubitemid 26001840)
36. Bloemenkamp KWM, Rosendaal FR, et al. Enhancement by factor v Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen. Lancet 1995;346:1593-6 (Pubitemid 26001841)
37. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82
38. Lidegaard O, Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception 1996;53:135-9 (Pubitemid 126351296)
39. MacRae K, Kay C. Third-generation oral contraceptive pills. BMJ 1995;311:1112
40. O'Brien PA. The third-generation oral contraceptive controversy. BMJ 1999;319:795-6
41. Heinemann LAJ, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328-36 (Pubitemid 46551070)
42. Spitzer WO, Lewis MA, Heinemann LA, et al. Third-generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:83-8
43. Lewis MA, Heinemann LA, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third-generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996;54:5-13 (Pubitemid 26230794)
44. Farmer RD, Lawrenson RA, Thompson CR, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8 (Pubitemid 27023424)
45. Farmer RD, Lawrenson RA, Todd JC, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000;49:580-90 (Pubitemid 30326558)
46. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third-generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000;321:1190-5
47. Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception 2001;64:125-33 (Pubitemid 33042599)
48. Kemmeren JM, Algra A, Grobbee DE. Third-generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:131-4 (Pubitemid 32678382)
49. Petitti DB. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003;349:1443-50 (Pubitemid 37211060)
50. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: nation follow-up study. BMJ 2009;339:b2890
51. Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423
52. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921
53. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005;7:409-16 (Pubitemid 40725775)
54. Lüdicke F, Gaspard UJ, Demeyer F, et al. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. Contraception 2002;66:411-15 (Pubitemid 37338056)
55. Zheng SR, Zheng HM, Qian SZ, et al. A randomized multicenter study comparing the efficacy and bleeding pattern of a single rod (Implanon) and a six capsule (Norplant) hormonal contraceptive implant. Contraception 1999;60:1-8
56. Olsson SE, Odlind V, Johansson E. Clinical results with subcutaneous implant containing 3-ketodesogestrel. Contraception 1990;42:1-11 (Pubitemid 20208807)
57. Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonorgestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009;91:1646-53
58. Funk S, Miller MM, Mishell DR Jr, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonorgestrel. Contraception 2005;71:319-26 (Pubitemid 40602307)
59. Mascarenhas L. Insertion and removal of Implanon: practical considerations. Eur J Contracept Reprod Health Care 2000;2:29-34 (Pubitemid 32171235)
60. Palomba S, Falbo A, Di Cello A, et al. Nexplanon: the new implant for long-term contraception. A comprehensive descriptive review. Gynecol Endocrinol 2012;28:710-21
61. Mansour D. Nexplanon: what Implanon did next. J Fam Plann Reprod Health Care 2010;36:187-9
62. Blumenthal PD, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability and clinical safety of Implanon. Eur J Contracept Reprod Health Care 2008;13:29-36
63. Mommers E, Blum GF, Gent TG, et al. Nexplanon, a radiopaque etonorgestrel implant in combination with a next-generation applicator: 3 years results of a noncomparative multicenter trial. Am J Obstet Gynecol 2012;207:388 e1-6
64. Dilbaz B, Ozdegirmenci O, Caliskan E, et al. Effect of desogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception 2010;81:510-14
65. Biswas A, Viegas OAC, Roy AC. Effect of Implanon-and Norplant-subdermal contraceptive implants on serum lipids-a randomized comparative study. Contraception 2003;68:189-93
66. Oderich CL, Wender MCO, Lubianca JN, et al. Impact of etonorgestrel-releasing implant and copper intrauterine device on carbohydrate metabolism: a comparative study. Contraception 2012;85:173-6
67. Biswas A, Viegas OAC, Coeling Bennink HJ, et al. Implanon-contraceptive implants: effects on carbohydrate metabolism. Contraception 2001;63:137-41
68. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with estrogen alone or in conjunction with progestogens results of a prospective study. Br Med J 1989;289:147-51 (Pubitemid 19039672)
69. Tikkanen MJ. Estrogen and progestins used in post menopausal replacement therapy as modulators of serum lipoproteins. In: Crepaldi G, et al. editors. Atherosclerosis VIII. Elsevier, Amsterdam; 1989. p. 765-8 (Pubitemid 19185178)
70. Saure A, Hirvonen E, Milsom I, et al. A randomized, double blind, multicenter study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms. Maturitas 1996;24:111-18
71. Marslew U, Riis BJ, Christiansen C. Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Eur J Clin Invest 1991;21:601-7
72. Saure A, Planellas J, Poulsen HK, Jaszczak P. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women. Maturitas 2000;34:133-42 (Pubitemid 30068652)
73. Nappi RE, Sances G, Allais G, et al. Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception 2011;83:223-8
74. Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M. Hormonal contraceptives and venous thromboembolism: An epidemiological update. Best Pract Res Clin Endocrinol Metab 2013;27:25-34
75. Lidegaard Ø, Milsom I, Geirsson RT, Skjeldestad FE. Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand 2012;91:769-78
76. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27 (Pubitemid 36999703)
77. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-11 (Pubitemid 350179584)
78. Kränzlin HT, Nap MA. The effect of a phasic oral contraceptive containing Desogestrel on seborrhea and acne. Eur J Contracept Reprod Health Care 2006;11:6-13
79. Clinical comparison of monophasic oral contraceptive preparations of gestodene/ethinyl estradiol and desogestrel/ethinyl estradiol. Latin American Oral Contraceptive Study Group. Contraception 1994;50:201-14
80. Luyckx AS, Gaspard UJ, Romus MA, et al. Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study. Fertil Steril 1986;45:635-42 (Pubitemid 16112282)
81. Kloosterboer HJ, van Wayjen RG, van den Ende A. Comparative effects of monophasic desogestrel plus ethinyloestradiol and triphasic levonorgestrel plus ethinyloestradiol on lipid metabolism. Contraception 1986;34:135-44 (Pubitemid 17178977)
82. Croxatto HB, Urbancsek J, Massai R, et al. A multicentre efficacy and safety study of the single contraceptive implant Implanon-. Hum Reprod 1999;14:976-81 (Pubitemid 29176477)